Lite Strategy, Inc. (LITS) AI Stock Analysis
LITS AI stock analysis summary
AI ResearchLite Strategy, Inc. is a clinical-stage biotechnology company developing cancer therapies that also holds Litecoin tokens as a primary reserve asset. While annual revenue expanded at a 3-year CAGR of 23.3% through FY2024 to reach $65.3M, trailing twelve month revenue stands at $0 as of June 30, 2026. The company carries a market cap of $35.0M and cash and short-term investments of $5.7M.
- Market cap
- $35.0M
- Revenue (TTM)
- $0
- P/E
- — fwd 4.6x
- 1Y return
- -37.8% S&P 500 16.8%
- Avg. target
- —
Bull case
- Lite Strategy generated $17.8M in net income with a 27.2% net margin in FY2024.
- The stock trades at a forward P/E of 4.6x, below the US-listed Healthcare median of 17.3x.
- Liquidity remains supported by a current ratio of 5.74 as of June 30, 2026.
Bear case
- Trailing twelve month revenue dropped to $0 as of June 30, 2026, with an EPS of -$2.06.
- Free cash flow remained negative across all reported annual periods, reaching -$50.5M in FY2024.
- The 5-year share count expanded by 477.0%, while the stock declined 97.5% over five years.
What Lite Strategy does
Lite Strategy, Inc., formerly known as MEI Pharma, Inc., is a clinical-stage pharmaceutical company based in San Diego, California. Incorporated in 2000, the company focuses on the development of novel and differentiated therapies for the treatment of cancer. In September 2025, it changed its name to Lite Strategy, Inc. and is also involved in holding Litecoin tokens as a primary reserve asset. The biotechnology firm operates with 5 employees.
Growth and profitability
Annual revenue grew from $34.8M in FY2021 to $40.7M in FY2022 and $48.8M in FY2023, reaching $65.3M in FY2024, representing a 3-year CAGR of 23.3%. Gross margin stood at 96.0% in FY2021 and was 100.0% across FY2022, FY2023, and FY2024. Operating margin moved from -173.7% in FY2021 to 22.3% in FY2024, while net income shifted from -$41.3M to $17.8M, or $4.30 per share. Research and development expense declined to $16.6M in FY2024 from $85.6M in FY2022. For the trailing twelve months ending June 30, 2026, revenue was $0 and EPS was -$2.06.
Balance sheet and cash flow
As of June 30, 2026, Lite Strategy held $5.7M in cash and short-term investments, total assets of $42.7M, and shareholders' equity of $41.6M. The company had a current ratio of 5.74. Free cash flow was -$50.5M in FY2024, matching an operating cash flow of -$50.5M. In FY2026, cash uses included $4.9M directed toward share buybacks, while the 5-year share count change was 477.0%.
Valuation and performance
Lite Strategy trades at a market cap of $35.0M and an enterprise value of $30.5M. The stock trades at a forward P/E of 4.6x, a price-to-sales of 0.3x, and an EV/EBITDA of 2.4x. These compare to medians for its US-listed Healthcare peer group of 17.3x forward P/E, 4.1x price-to-sales, and 12.0x EV/EBITDA. Over the past year, the stock dropped 37.8% compared to a 16.8% return for the S&P 500, and over five years it fell 97.5% versus an 83.0% gain for the benchmark.
What analysts expect
Lite Strategy beat EPS estimates in 2 of the last 4 quarters. The company's next earnings date is scheduled for November 13, 2026. Institutional investors hold 19.4% of the shares, while insider ownership accounts for 1.4%, and short interest represents 0.6% of the float.
Key risks and what to watch
- Cash and short-term investments totaled $5.7M as of June 30, 2026, following FY2024 operating cash burn of -$50.5M.
- Return on equity for the trailing twelve months was -243.0%, reflecting significant losses relative to equity.
- The company operates with 5 employees, creating operational concentration risk in executing clinical development.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this LITS AI stock analysis
This page is an AI-written research summary of Lite Strategy, Inc. (LITS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: LITS income statement, LITS balance sheet, LITS key metrics, LITS chart. See the LITS stock overview for the latest quote and news.
LITS AI stock analysis FAQ
What is Lite Strategy's core business model?
Lite Strategy, Inc. is a clinical-stage pharmaceutical firm focused on therapies for cancer treatment. In addition to clinical development, the company holds Litecoin tokens as a primary reserve asset.
What was Lite Strategy's latest reported financial performance?
For the trailing twelve months ended June 30, 2026, Lite Strategy reported $0 in revenue and an EPS of -$2.06. In FY2024, the company recorded $65.3M in revenue and $17.8M in net income.
How does Lite Strategy's valuation compare to sector peers?
Lite Strategy trades at a forward P/E of 4.6x and an EV/EBITDA of 2.4x. This compares to the US-listed Healthcare median forward P/E of 17.3x and EV/EBITDA of 12.0x.
Does Lite Strategy pay a dividend?
Lite Strategy does not pay a dividend. Capital allocation in FY2026 included $4.9M used for share buybacks.